JP2690215B2 - 無細胞抗百日咳菌ワクチン - Google Patents

無細胞抗百日咳菌ワクチン

Info

Publication number
JP2690215B2
JP2690215B2 JP3175819A JP17581991A JP2690215B2 JP 2690215 B2 JP2690215 B2 JP 2690215B2 JP 3175819 A JP3175819 A JP 3175819A JP 17581991 A JP17581991 A JP 17581991A JP 2690215 B2 JP2690215 B2 JP 2690215B2
Authority
JP
Japan
Prior art keywords
amino acid
vaccine
pertussis
replaced
fha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP3175819A
Other languages
English (en)
Japanese (ja)
Other versions
JPH04368337A (ja
Inventor
ネンチョーニ ルチャーノ
ブニョーリ マッスィモ
マネッティ ロベルト
マルスィリ イリオ
ルッジェロ パオロ
ラップオリ リノ
Original Assignee
スクラヴォ エス ピー エイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11170908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2690215(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by スクラヴォ エス ピー エイ filed Critical スクラヴォ エス ピー エイ
Publication of JPH04368337A publication Critical patent/JPH04368337A/ja
Application granted granted Critical
Publication of JP2690215B2 publication Critical patent/JP2690215B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP3175819A 1990-06-21 1991-06-21 無細胞抗百日咳菌ワクチン Expired - Lifetime JP2690215B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT02071090A IT1248735B (it) 1990-06-21 1990-06-21 Vaccini acellulari contro la pertosse
IT20710A/90 1990-06-21

Publications (2)

Publication Number Publication Date
JPH04368337A JPH04368337A (ja) 1992-12-21
JP2690215B2 true JP2690215B2 (ja) 1997-12-10

Family

ID=11170908

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3175819A Expired - Lifetime JP2690215B2 (ja) 1990-06-21 1991-06-21 無細胞抗百日咳菌ワクチン

Country Status (4)

Country Link
EP (1) EP0462534A3 (2)
JP (1) JP2690215B2 (2)
CA (1) CA2045071A1 (2)
IT (1) IT1248735B (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412207D0 (en) * 1984-05-12 1984-06-20 Wellcome Found Antigenic preparations
GB8910570D0 (en) 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
US5856122A (en) * 1993-08-24 1999-01-05 University Of Alberta Modification of pertussis toxin
WO1995009649A1 (en) 1993-10-05 1995-04-13 Medeva Holdings B.V. Vaccine compositions
JP5148577B2 (ja) * 1993-12-22 2013-02-20 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 非毒性の粘膜アジュバント
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6051240A (en) * 1994-04-28 2000-04-18 Takeda Chemical Industries, Ltd. Method of separating protective components of Bordetella pertussis
US20030072774A1 (en) * 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
GB9500788D0 (en) * 1995-01-16 1995-03-08 Medeva Holdings Bv Vaccine compositions
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
RU2130778C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
GB9923060D0 (en) * 1999-09-29 1999-12-01 Chiron Spa Vaccine
EP2430040A1 (en) 2009-05-11 2012-03-21 Novartis AG Antigen purification process for pertactin antigen
MX372965B (es) * 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
BR112021007668A2 (pt) * 2018-11-06 2021-07-27 Glaxosmithkline Biologicals S.A. composições imunogênicas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6176422A (ja) * 1984-09-22 1986-04-18 Chemo Sero Therapeut Res Inst 百日ぜきコンポ−ネントワクチンおよび百日ぜき・ジフテリア・破傷風混合ワクチンの製造方法
IT1223334B (it) * 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
AP8900132A0 (en) * 1988-07-22 1991-01-14 Smithkline Biolog Bordetella pertussis vaccine
ES2078258T3 (es) * 1989-04-28 1995-12-16 Sclavo Spa Mutantes de toxina pertussica, cepas de bordetella capaces de producir tales mutantes y su uso en el desarrollo de vacunas antipertussicas.
WO1991008294A1 (en) * 1989-11-29 1991-06-13 Smithkline Beecham Biologicals (S.A.) Novel vaccine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｉｎｆｅｃｔｉｏｎ ａｎｄ Ｉｍｍｕｎｉｔｙ，Ｖｏｌ．５６，Ｎｏ．１２ （１９８８），Ｐ．３１８９−３１９５
Ｉｎｆｅｃｔｉｏｎ ａｎｄ Ｉｍｍｕｎｉｔｙ，Ｖｏｌ．５８，Ｎｏ．５ （Ｍａｙ １９９０），Ｐ．１３０８−１３１５
Ｓｃｉｅｎｃｅ，Ｖｏｌ．２４６ （１９８９） Ｐ．４９７−５００

Also Published As

Publication number Publication date
IT9020710A0 (2) 1990-06-21
EP0462534A3 (en) 1992-12-02
CA2045071A1 (en) 1991-12-22
JPH04368337A (ja) 1992-12-21
IT1248735B (it) 1995-01-26
IT9020710A1 (it) 1991-12-21
EP0462534A2 (en) 1991-12-27

Similar Documents

Publication Publication Date Title
JP2690215B2 (ja) 無細胞抗百日咳菌ワクチン
Andrews et al. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge
JP5830009B2 (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対して免疫化するための組成物
Holmgren et al. Mechanisms of disease and immunity in cholera: a review
EP0453024B1 (en) Actinobacillus pleuropneumoniae subunit vaccine
US5750115A (en) Escherichia coli vaccine
EP0549617A1 (en) IMPROVED VACCINE COMPOSITION.
Sjöstedt et al. The T-cell-stimulating 17-kilodalton protein of Francisella tularensis LVS is a lipoprotein
US5807685A (en) OspE, OspF, and S1 polypeptides in Borrelia burgdorferi
JPH11507805A (ja) 非細胞性百日咳ワクチンおよびその製造方法
AU669674B2 (en) Treponema hyodysenteriae vaccine
von Specht et al. Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers
PT680765E (pt) Vacina para estirpe não tipável de haemophilus influenzae.
JPH10510984A (ja) 無細胞性抗ボルデテラワクチン
US6994854B1 (en) Protective epitopes of adenyl cyclase-haemolysin (AC-Hly), their application to the treatment or to the prevention of bordetella infections
Yang et al. Effect of lipid modification on the physicochemical, structural, antigenic and immunoprotective properties of Haemophilus influenzae outer membrane protein P6
EP0550683B1 (en) Vaccine suitable for combatting bordetella pertussis
Idänpään-Heikkilä et al. Immunization with meningococcal class 1 outer membrane protein produced in Bacillus subtilis and reconstituted in the presence of Zwittergent or Triton X-100
JP2015536929A (ja) スタフィロコッカス・アウレウスｓｄｒｅｃｎａｂドメイン及びワクチン接種のためのその使用
Burnette et al. Properties of pertussis toxin B oligomer assembled in vitro from recombinant polypeptides produced by Escherichia coli
US20230104241A1 (en) Protective staphylococcal exotoxin vaccine
Hausman et al. Immune response to dimeric subunits of the pertussis toxin B oligomer
US6716591B1 (en) B. burgdorferi polypeptides
Ölander et al. Immunogenicity and protective efficacy of pertussis toxin subunit S1 produced by Bacillus subtilis
WO1992019757A1 (en) Recombinant b oligomer of pertussis toxin

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 19960118